The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
Re Liambooth statement "Unlike others. Trinity like Futura have also covered themselves “ Source: Futura Medical Note: 1 – for illustrative purposes only as data is derived from different clinical studies”"
And what does it say on the TWO ANOYMOUS articles you keep posting and make claims of and your referenced over hundreds of times as they are the integral to what you are saying.
Well as well as being written by Anonymous people, the websites they are posted on cover them selves also see below (JUST LIKE ALL WEBSITES DO - DUH)
SMSNA
"Disclaimer
The information on this website is intended for educational purposes only. It is not intended to be used for the diagnosis or treatment of any specific medical condition, which should only be done by a qualified physician or health care professional."
Kalmbach (Discovery) article posted..says payment, so anonymous poster paid and the website etc?
Your interactions with organizations and/or individuals, including payment and delivery of goods or services, and any other terms, conditions, warranties or representations associated with such dealings, are solely between you and such organizations and/or individuals.
You agree that Kalmbach Publishing Co. shall not be responsible or liable for any loss or damage of any sort incurred as the result of any such dealings.
In the event that you have a dispute with one or more other users, you hereby release Kalmbach Publishing Co., its officers, employees, agents and successors in rights from claims, demands and damages (actual and consequential) of every kind or nature, known or unknown, suspected and unsuspected, disclosed and undisclosed, arising out of or in any way related to such disputes and/or our service.
..... While we prohibit such conduct and content on our site, you understand and agree that Kalmbach Publishing Co. cannot be responsible for the content posted on its sites and you nonetheless may be exposed to such materials and that you use the sites at your own risk.
So basically you have no actual proof
Enough said.
"There will be no such inclusion criteria in the real world" - YES many millions of people in the real world with ED would say YES to the same I/E criteria which is " ‘At home over the past 3 months, have you experienced at least some growth of your ***** in response to: (1) mechanical stimulation by yourself or your partner, or (2) visual stimulation?’
"One thing is for sure the ASA and other consumer bodies will be definitely getting reports of misleading advertising when some ED consumers find it doesn’t work for them and why based on the clinical setting it was tested in."
Where is your proof? " when some ED consumers find it doesn’t work for them and why based on the clinical setting it was tested in" - Provide hard evidence since you are so sure.
If you have it the hard evidence, about all your claims like these, then sure. Otherwise its just share bashing again and again
with no evidence to back up your claims.
Made up BS because you are a share basher
ABOUT LIAMBOOTH
Liambooth joined LSE March 2021 when Fum spiked in price
- Same time in March 2021 Fum was shorted "Fum have 5.7m shares out on loan (being shorted) which is 2.08% of the total share allocation."
- Since March 2021 Liambooth has posted 1000+ negative posts on LSE, misleading, distorted and untrue claims with no real hard evidence of anything.
- Liambooth posted hundreds more negative posts on ADVN, and no posts before March 2021 neither, check yourselves
- He ain't a LTH, he lying to you all.
- He clearly is a stock basher. Lying and deceiving in his posts
So don't entertain or believe a word he is saying, he is a proven share basher.
LSE won't do a thing.
You can share bash as much as you like. The experts say
"“The efficacy of MED3000 is remarkable and approaches the efficacy of current first line therapy but with significantly lower adverse events"
&
“All formulations tested in FM57, including the control product DermaSys®, have demonstrated positive and statistically significant efficacy results against baseline data together with an excellent safety profile,”
&
“In my humble opinion and as an expert in the field of erectile dysfunction management, I am very supportive of MED3000 and do believe that it offers an important and valid addition to the armamentarium of treatments we can offer our patients for erectile dysfunction”
BUT YOU THE SHARE BASHER ARE THE ONLY ONE THAT SAYS IT DOES NOT AND TWO ANONYMOUS ARTICLES
Plus yes they can compare to Cialis, etc, they have done, the experts have and it is in the patent. Tough, don't matter what you say.
plus the study was a reflect of the real world, it was in patients with ED and there are millions of ED suffers in the world.
ABOUT LIAMBOOTH
Liambooth joined LSE March 2021 when Fum spiked in price
- Same time in March 2021 Fum was shorted "Fum have 5.7m shares out on loan (being shorted) which is 2.08% of the total share allocation."
- Since March 2021 Liambooth has posted 1000+ negative posts on LSE, misleading, distorted and untrue claims with no real hard evidence of anything.
- Liambooth posted hundreds more negative posts on ADVN, and no posts before March 2021 neither, check yourselves
- He ain't a LTH, he lying to you all.
- He clearly is a stock basher. Lying and deceiving in his posts
So don't entertain or believe a word he is saying, he is a proven share basher.
LSE won't do a thing.
Are the experts right or is Liambooth
PS have i mentioned to you all (ABOUT SHAREBASHER LIAMBOOTH)
Liambooth joined LSE March 2021 when Fum spiked in price
- Same time in March 2021 Fum was shorted "Fum have 5.7m shares out on loan (being shorted) which is 2.08% of the total share allocation."
- Since March 2021 Liambooth has posted 1000+ negative posts on LSE, misleading, distorted and untrue claims with no real hard evidence of anything.
- Liambooth posted hundreds more negative posts on ADVN, and no posts before March 2021 neither, check yourselves
- He ain't a LTH, he lying to you all.
- He clearly is a stock basher. Lying and deceiving in his posts
So don't entertain or believe a word he is saying, he is a proven share basher.
LSE won't do a thing.
Liambooth last post is claiming the results in improvement of ED in the FM57 clinical trial are all because of the 15 second manual rubbing of the gel and not because of the of MED3000.
As I have asked you many many times, show me where evidence, the clinical data to back up your claims, that the clinical trial results showed it is not MED3000 but the rubbing of the gel.
Liambooth claimed for many months Lubricants can do the same as MED3000. Where is your clinical data that shows the same results if not better for lubricants than MED3000 for IIEF, SEP2, SEP3 in a phase 3, 12 week treatment clinical trial setting, in multiple Inv sites
As the experts say:
“The efficacy of MED3000 is remarkable and approaches the efficacy of current first line therapy but with significantly lower adverse events. With topical application, it will be of particular appeal to patients who want a fast onset of action. Lack of drug interactions with prescription products will enable the product to be used with other medications such as nitrates and other cardiovascular drugs. It can also be used in conjunction with other ED products to improve overall efficacy to patients. As such MED3000 will be of great interest to the medical community.”
Professor David Ralph
Consultant Urologist at University College London and past president of the European Society of Sexual Medicine
=========
“All formulations tested in FM57, including the control product DermaSys®, have demonstrated positive and statistically significant efficacy results against baseline data together with an excellent safety profile,”
“The DermaSys® product will be of high interest to the Medical Community for those patients who seeking a rapid onset of action and a very low side-effect profile. It will likely find use in the substantial number of patients, especially those with ED of a mild to moderate nature and those patients who are contraindicated for use with existing products.”
Said Dr. Yacov Reisman, Consultant Urologist and president of the European Society of Sexual Medicine.
========
“In my humble opinion and as an expert in the field of erectile dysfunction management, I am very supportive of MED3000 and do believe that it offers an important and valid addition to the armamentarium of treatments we can offer our patients for erectile dysfunction”
Professor Arthur Burnett
Johns Hopkins University School of Medicine, Baltimore, US
MD, MBA, FACS, Patrick C Walsh Distinguished Professor of Urology
Past President of the Sexual Medicine Society of North America
“The efficacy of MED3000 is remarkable and approaches the efficacy of current first line therapy but with significantly lower adverse events. With topical application, it will be of particular appeal to patients who want a fast onset of action. Lack of drug interactions with prescription products will enable the product to be used with other medications such as nitrates and other cardiovascular drugs. It can also be used in conjunction with other ED products to improve overall efficacy to patients. As such MED3000 will be of great interest to the medical community.”
Professor David Ralph
Consultant Urologist at University College London and past president of the European Society of Sexual Medicine
=========
“All formulations tested in FM57, including the control product DermaSys®, have demonstrated positive and statistically significant efficacy results against baseline data together with an excellent safety profile,”
“The DermaSys® product will be of high interest to the Medical Community for those patients who seeking a rapid onset of action and a very low side-effect profile. It will likely find use in the substantial number of patients, especially those with ED of a mild to moderate nature and those patients who are contraindicated for use with existing products.”
Said Dr. Yacov Reisman, Consultant Urologist and president of the European Society of Sexual Medicine.
========
“In my humble opinion and as an expert in the field of erectile dysfunction management, I am very supportive of MED3000 and do believe that it offers an important and valid addition to the armamentarium of treatments we can offer our patients for erectile dysfunction”
Professor Arthur Burnett
Johns Hopkins University School of Medicine, Baltimore, US
MD, MBA, FACS, Patrick C Walsh Distinguished Professor of Urology
Past President of the Sexual Medicine Society of North America
Liamboth is wrong.
MED3000 onset time is faster that oral viagra / Cialis. The ED experts say so.
You claim is it is not, because of manual rubbing in of MED3000 for 15 seconds. Show the evidence, hard clinical data results that all changes from baseline, IEFF, SEP2 and SEP 3, is to do with rubbing in the gel and not a result of MED300 effects.
You just making sweeping assumptions and lies with no evidence. Because your a share basher.
Liambooth joined LSE March 2021 when Fum spiked in price
- Same time in March 2021 Fum was shorted "Fum have 5.7m shares out on loan (being shorted) which is 2.08% of the total share allocation."
- Since March 2021 Liambooth has posted 1000+ negative posts on LSE, misleading, distorted and untrue claims with no real hard evidence of anything.
- Liambooth posted hundreds more negative posts on ADVN, and no posts before March 2021 neither, check yourselves
- He ain't a LTH, he lying to you all.
- He clearly is a stock basher. Lying and deceiving in his posts
So don't entertain or believe a word he is saying, he is a proven share basher.
LSE won't do a thing.
Liambooth joined LSE March 2021 when Fum spiked in price
- Same time in March 2021 Fum was shorted "Fum have 5.7m shares out on loan (being shorted) which is 2.08% of the total share allocation."
- Since March 2021 Liambooth has posted 1000+ negative posts on LSE, misleading, distorted and untrue claims with no real hard evidence of anything.
- Liambooth posted hundreds more negative posts on ADVN, and no posts before March 2021 neither, check yourselves
- He ain't a LTH, he lying to you all.
- He clearly is a stock basher. Lying and deceiving in his posts
The I/E protocol is in the public domain for anyone to see.
Also Re "Why is this inclusion criteria not being mentioned on the Eroxon website under How do I know if Eroxon® is suitable for me? Eroxon® will be labelled very clearly and will contain a leaflet with warnings and precautions. Please check the label carefully before purchase and if in doubt ask the pharmacist or consult a doctor before use."
Same reason when you go to by Viagra the I/E criteria is not mentioned. Not on websites, what the i/E criteria is for Viagra/ Cialis from their trials. This is no different. It is a i/E criteria for a clinical trial, not a who can and cannot take it.
These points and other points, have been discussed many many times before but the sharebasher keeps pasting back the same things again and again, when they been discussed here on this board many times.
HE IS A PAID SHARE BASHER, HERE FACTS ABOUT LIAMBOOTH.
Liambooth joined LSE March 2021 when Fum spiked in price
- Same time in March 2021 Fum was shorted "Fum have 5.7m shares out on loan (being shorted) which is 2.08% of the total share allocation."
- Since March 2021 Liambooth has posted 1000+ negative posts on LSE, misleading, distorted and untrue claims with no real hard evidence of anything.
- Liambooth posted hundreds more negative posts on ADVN, and no posts before March 2021 neither, check yourselves
- He ain't a LTH, he lying to you all.
- He clearly is a stock basher. Lying and deceiving in his posts
There is no omission of the information about the FM57 inclusion criteria by the director or anyone at FUM.
It is in the protocol, it is all over clinicaltrials.gov, it was known to all participants all 1200, all investigators, regulatory bodies, investors, every one that wants to know it is out there in the public.
The CSR, protocol, technical dossiers and other documents are all sent to regulatory authorities.
It's been debated on here to death
But the share basher Liambooth keeps posting points he has been shown as wrong no before. Because he is a share basher.
Neither is it significant at all.
Detailed analysis of the pivotal FM57 data shows remarkably consistent outcomes for MED3000 across all treatment groups. There are clear and statistically meaningful improvements for the three co-primary endpoints, and also statistical superiority over baseline for Mild, Moderate, and Severe forms of ED (erectile dysfunction). The results are consistent when viewed across patient groups, study centres, geographies, and CROs performing the trial.
There are clear and statistically meaningful improvements. Increase from Baseline.
Experts say efficacy nearing that of first line treatment. They had ALL the information before making those statements.
It works, the end.
The share basher has a short and wants to scare and make up total lies, not got a leg to stand on, always .
HE IS A PAID SHARE BASHER, HERE FACTS ABOUT LIAMBOOTH.
Liambooth joined LSE March 2021 when Fum spiked in price
- Same time in March 2021 Fum was shorted "Fum have 5.7m shares out on loan (being shorted) which is 2.08% of the total share allocation."
- Since March 2021 Liambooth has posted 1000+ negative posts on LSE, misleading, distorted and untrue claims with no real hard evidence of anything.
- Liambooth posted hundreds more negative posts on ADVN, and no posts before March 2021 neither, check yourselves
- He ain't a LTH, he lying to you all.
- He clearly is a stock basher. Lying and deceiving in his posts
BTW, you ask me about T&Cs and to answers your questions (which I done)
but you run a way like a little P**sy when any one asks you to provide any evidence to support any of your claim
NO NEED TO REPLY. The whole Board knows. It is because you are a proven share basher.
Wetting myself. and ROFLMAO
@Liambooth - Everyone knows your a share basher, LOL and as you once quoted: "Better to remain silent and be thought a fool than to speak and to remove all doubt" — ABRAHAM LINCOLN.
Too late to for you
I must mention again, Laimbooth doesn't realise what the whole board is seeing and knowS about him. HE IS A PAID SHARE BASHER, HERE FACTS ABOUT LIAMBOOTH.
Liambooth joined LSE March 2021 when Fum spiked in price
- Same time in March 2021 Fum was shorted "Fum have 5.7m shares out on loan (being shorted) which is 2.08% of the total share allocation."
- Since March 2021 Liambooth has posted 1000+ negative posts on LSE, misleading, distorted and untrue claims with no real hard evidence of anything.
- Liambooth posted hundreds more negative posts on ADVN, and no posts before March 2021 neither, check yourselves
- He ain't a LTH, he lying to you all.
- He clearly is a stock basher. Lying and deceiving in his posts
PS have i mentioned to you all (IMPORTANT FACTS ABOUT SHAREBASHER LIAMBOOTH)
Liambooth joined LSE March 2021 when Fum spiked in price
- Same time in March 2021 Fum was shorted "Fum have 5.7m shares out on loan (being shorted) which is 2.08% of the total share allocation."
- Since March 2021 Liambooth has posted 1000+ negative posts on LSE, misleading, distorted and untrue claims with no real hard evidence of anything.
- Liambooth posted hundreds more negative posts on ADVN, and no posts before March 2021 neither, check yourselves
- He ain't a LTH, he lying to you all.
- He clearly is a stock basher. Lying and deceiving in his posts
So don't entertain or believe a word he is saying, he is a proven share basher.
LSE won't do a thing.
And yes Quid Pro Quo, ROFLMAO wetting pants and quoting Lincoln.
First OTC gel for ED.
No competitors,
No other gels can claim this, no doctor or pharmacist assessment.
Available without prescription for ED
First to market
Why it is the only OC gel. Because there is no other
Nothing like it can claim equivalence, MOA substances, cooling and heating ranges, Ph, viscosity, clinical results,
coming soon
See here.
https://eroxon.com/
PS have i mentioned to you all (IMPORTANT FACTS ABOUT SHAREBASHER LIAMBOOTH)
Liambooth joined LSE March 2021 when Fum spiked in price
- Same time in March 2021 Fum was shorted "Fum have 5.7m shares out on loan (being shorted) which is 2.08% of the total share allocation."
- Since March 2021 Liambooth has posted 1000+ negative posts on LSE, misleading, distorted and untrue claims with no real hard evidence of anything.
- Liambooth posted hundreds more negative posts on ADVN, and no posts before March 2021 neither, check yourselves
- He ain't a LTH, he lying to you all.
- He clearly is a stock basher. Lying and deceiving in his posts
So don't entertain or believe a word he is saying, he is a proven share basher.
LSE won't do a thing.
And yes Quid Pro Quo, ROFLMAO wetting pants and quoting Lincoln.
Re Liambooth last post "Still no answer? Why did Futura have to put “for illustrative purposes only as data is derived from different clinical studies’"
I have already replied back: ssl1975, Posted in: FUM, Posts: 484, Price: 32.80, No Opinion, RE: very positive28 Nov 2021 18:28
Tells me the share bashing employees don't communicate vey much to get their story right. more holes than (well you can all answer back, clean or not )
Let me repeat the simple fact as I did back in my reply to THE SHARE BASHER LIAM BOOTH (ROFLMOA)
Same reason as all websites / disclosure of data / public releases / article have T&C's including her some of his own articles he loves to post. Both Anonymous by the way. But one is quite damming, (THE KALMBACH) - stating posters are paid to write articles and they are not responsible for what they post!!!!, just as the anonymous writer was?
SMSNA
"Disclaimer
The information on this website is intended for educational purposes only. It is not intended to be used for the diagnosis or treatment of any specific medical condition, which should only be done by a qualified physician or health care professional."
And you keep claiming it should be accepted LMAO. Even they say. It's educational only, but seek professional opinion by "qualified physician or health care professional."
Kalmbach (Discovery) article posted..says payment etc?
Your interactions with organizations and/or individuals, including payment and delivery of goods or services, and any other terms, conditions, warranties or representations associated with such dealings, are solely between you and such organizations and/or individuals. You should make whatever investigation you feel necessary or appropriate before proceeding with any online or offline transaction with any of these organizations or individuals.
You agree that Kalmbach Publishing Co. shall not be responsible or liable for any loss or damage of any sort incurred as the result of any such dealings. If there is a dispute between participants on this site, or between users and any third party, you understand and agree that Kalmbach Publishing Co. is under no obligation to become involved. In the event that you have a dispute with one or more other users, you hereby release Kalmbach Publishing Co., its officers, employees, agents and successors in rights from claims, demands and damages (actual and consequential) of every kind or nature, known or unknown, suspected and unsuspected, disclosed and undisclosed, arising out of or in any way related to such disputes and/or our service.
Violation of any of these agreements will result in the termination of your account with the sites. While we prohibit such conduct and content on our site, you understand and agree that Kalmbach Publishing Co. cannot be responsible for the content posted on its sites and you nonetheless may be exposed to such materials and that you use the sites at your own risk.
hahaha
Eroxon® is a gel applied to the glans (head) of the *****, clinically proven to treat erectile dysfunction in men.
https://eroxon.com/
Clinically proven, ROFLMAO wetting my pants.
What is not to love – Eroxon /MED3000 - HERE ARE THE FACTS
- Eroxon going to market. VERY SOON
- FIRST GEL FOR ED TO OTC MARKET - NO OTHER GELS CAN. NO COMPETITION. NO BRAINER
- $3.6 billion market & conservative 5% share of that estimated as min
- Can be used with other products / medicine or recreationally (as some would)
- Less AE's than say Cialis, Viagra etc
- Experts say efficacy approach that of fist line treatments
- EU approved, US approval in process, Global approvals ongoing
- UK / EU partnership / launch COMING SOON
- South America and Mexico launch COMING SOON
- China and SE Asia launch COMING SOON
- US go ahead COMING SOON
- Patent application in progress using patent lawyers - Approval COMING SOON
- Will help ED sufferers - COMING SOON TO MILLIONS of ED SUFFERERS GLOBALLY
- Fast-acting and helps you get an erection within 10 minutes. (FASTER THAN CIALIS, VIAGRA ETC)
- First fast-acting topical gel for erectile dysfunction available WITHOUT A DOCTORS PRESCRIPTION in Europe and the UK.
- No need for questionnaires or pharmacists Assessment unlike first line treatments
- Eroxon® is clinically proven to treat erectile dysfunction and following a large Phase 3 clinical trial was approved in April 2021 for marketing in the EU and UK.